Mountain View, CA December 15, 2011 Metabolomx, a diagnostic company focused on the detection of the metabolomics signature of cancer from exhaled breath, today announces publication of results from the first clinical study demonstrating a breath test that can both detect lung cancer and differentiate between types of lung cancer in humans. This seminal study, conducted at the Cleveland Clinic and led by Dr. Peter Mazzone, used Metabolomx' first-generation colorimetric sensor array, and reported accuracy exceeding 80% in lung cancer detection, comparable to computerized tomography (CT) scan. Further, the study found that Metabolomx' first-generation colorimetric sensor array could identify the subtype of lung cancer (small cell versus adenocarcinoma versus squamous cell) with accuracy approaching 90%.
The availability of a low-cost, non-invasive metabolomic breath signature for lung cancer is particularly timely given the recently announced results of the National Cancer Institute's National Lung Screening Trial (NLST) calling for wider CT screening of high-risk citizens. The breath signature, which reports active tumor metabolism, is thought to provide complementary information to CT, potentially helping clinicians distinguish benign from malignant lung nodules.
The sensor detects the unique pattern of volatile organic compounds (the "metabolic biosignature") present in exhaled breath. The article, "Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer," is appearing in the current, online issue of the Journal of Thoracic Oncology (JTO), the official Journal of the International Association for the Study of Lung Cancer.
James R. Jett, MD, Pulmonary Medicine and Medical Oncology, National Jewish Health and Editor-in-Chief of the Journal of Thoracic Oncology, stated, "The JTO is dedicated to publishing the best in clinical research that may one day ma
|Contact: Justin Jackson|